Lilly Acquires Centessa, Bolstering Sleep-Wake Disorder Pipeline
Event summary
- Lilly acquires Centessa Pharmaceuticals for an undisclosed sum on March 31, 2026.
- Centessa’s OX2R agonist pipeline, co-developed with Nxera, includes cleminorexton, ORX142, and ORX489.
- Nxera retains economic interest via milestone payments, royalties, and equity in Centessa.
- Nxera’s separate 2022 collaboration with Lilly on metabolic diseases remains active, with up to $694M in potential milestones.
The big picture
Lilly’s acquisition of Centessa underscores the growing consolidation in the CNS drug space, particularly around sleep-wake disorders. The deal highlights the strategic value of Nxera’s NxStaR™ and NxWave™ platforms, which have now attracted partnerships with multiple top-tier pharma companies. The transaction also signals Lilly’s commitment to expanding its neurology portfolio, following similar moves by competitors in the space.
What we're watching
- Pipeline Integration
- How Lilly will integrate Centessa’s OX2R agonist pipeline into its existing sleep-wake disorder portfolio.
- Financial Impact
- Whether Nxera’s milestone payments and royalties from the OX2R agonists will materially boost its revenue.
- Strategic Alignment
- The pace at which Nxera advances its wholly owned metabolic and rare endocrine disease pipeline.
Related topics